These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors. Prabhakaran K, Harris EB, Randhawa B. Microbios; 1997; 91(366):7-14. PubMed ID: 9467917 [Abstract] [Full Text] [Related]
12. [A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis]. Nakagawa Y, Shimazu K, Ebihara M, Aman K. Kekkaku; 1999 May; 74(5):447-52. PubMed ID: 10386034 [Abstract] [Full Text] [Related]
14. Pharmacokinetic properties of beta-lactamase inhibitors. de la Pena A, Derendorf H. Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170 [Abstract] [Full Text] [Related]
17. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. Dinçer I, Ergin A, Kocagöz T. Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094 [Abstract] [Full Text] [Related]